Cannabics pharmaceuticals lll Nachrichten zu Cannabics Pharmaceuticals Analysen aktuelle News jetzt einfach und schnell bei ariva.de ansehen. Cannabics pharmaceuticals Cannabics pharmaceuticals Live-Diagramm von Cannabics Pharmaceuticals Inc und Echtzeit-Preisaktualisierungen anzeigen. Cannabics pharmaceuticals Zu der Cannabics Pharmaceuticals Aktie WKN A116WM, ISIN US13764M1009 finden Sie hier Analysen, News, Kurse, Charts, Diskussionen,.Die Aktienkurse aller wichtigen B rsenpl tze zu Cannabics Pharmaceuticals-Aktie auf einen Blick. Aktienkurse, Ums tze, Ask, Bid, Volumen der B rsenpl tze von Cannabics Pharmaceuticals-Aktie. Cannabics pharmaceuticals Das KUV von Cannabics Pharmaceuticals 2023 ist 0. Cannabics pharmaceuticals Cannabics Pharmaceuticals Aktie - Aktuelle Kurse und Unternehmensdaten. Finanzsoftware die Spa macht - kostenlos. US13764M1009. Close sidebar. Portfolio-Tracking Watchlists M rkte Dividendenkalender Community Blog Registrieren Anmelden Aktie. US13764M1009. A116WM. CNBX. Cannabics Pharmaceuticals . Cannabics pharmaceuticals Just Announced Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program. Cannabics pharmaceuticals bersicht ber Kursziele der CANNABICS PHARMACEUTICALS AKTIE, historische Kursziele und Kursziel im Branchenvergleich. Cannabics pharmaceuticals Das ROA Return on Assets von Cannabics Pharmaceuticals 2024 ist -7,42. Im Jahr 2024 betrug die Rendite auf das Gesamtverm gen ROA von Cannabics Pharmaceuticals -7,42, ein Cannabics pharmaceuticals Introduction to Cannabics Pharmaceuticals Inc. Lab Cannabics pharmaceuticals Das Eigenkapital von Cannabics Pharmaceuticals 2024 ist -2,02 Mio. USD. Im Jahr 2024 betrug das Eigenkapital von Cannabics Pharmaceuticals -2,02 Mio. USD, ein Anstieg um 23,93 gegen ber dem -1,63 Mio. USD Eigenkapital im vorherigen Jahr. Cannabics pharmaceuticals Die Verbindlichkeiten von Cannabics Pharmaceuticals 2023 ist 0. Cannabics pharmaceuticals Das KUV von Cannabics Pharmaceuticals 2023 ist 0. Cannabics pharmaceuticals Cannabics pharmaceuticals Cannabics Pharmaceuticals Automated Robotic High Throughput Screening Facility in Rehovot, Israel Cannabics pharmaceuticals Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals TEL AVIV, Israel and BETHESDA, Md., March 28, 2022 PRNewswire - Cannabics Pharmaceuticals Inc. OTCQB CNBX , a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has changed its corporate name to CNBX Pharmaceuticals Cannabics pharmaceuticals Aktienanalyse Cannabics Pharmaceuticals Inc Die Cannabics Pharmaceuticals Inc WKN US13764M1009 ist ein f hrendes Unternehmen in der medizinischen Cannabisbranche. Das Cannabics pharmaceuticals Cannabics Pharmaceuticals Inc. Vorstellung des Unternehmens Cannabics Pharmaceuticals Inc., Aktion re, Vorst nde und Berufsbeschreibung, Finanzst rkerating . Cannabics pharmaceuticals Die Mitarbeiteranzahl von Cannabics Pharmaceuticals 2023 ist 0. Cannabics pharmaceuticals Verschuldung von Cannabics Pharmaceuticals 2023 ist 0. Cannabics pharmaceuticals Das ROE Return on Equity von Cannabics Pharmaceuticals 2023 ist 0. Cannabics pharmaceuticals Cannabics Pharmaceuticals Inc. News, Nachrichten und Informationen Aktie Cannabics Pharmaceuticals Inc. A116WM US13764M1009 Other OTC 95.4duba1pwujnB Cannabics pharmaceuticals About Cannabics Pharmaceuticals. Headquartered in Tel-Aviv, Israel, Cannabics Pharmaceuticals Inc. CNBX is a U.S public company that is developing a platform which leverages novel drug-screening . Cannabics pharmaceuticals About Cannabics Pharmaceuticals Cannabics Pharmaceuticals Inc. OTCQB CNBX is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The . Cannabics pharmaceuticals Das KGV von Cannabics Pharmaceuticals 2023 ist -1,35. Cannabics pharmaceuticals Cannabics pharmaceuticals Cannabics Pharmaceuticals CNBX IR FORM 10-K 2014Q4 Cannabics pharmaceuticals Verschuldung von Cannabics Pharmaceuticals 2023 ist 0. Cannabics pharmaceuticals Cannabics Pharmaceuticals Inc. News, Nachrichten und Informationen Aktie Cannabics Pharmaceuticals Inc. A116WM US13764M1009 Other OTC Cannabics pharmaceuticals BETHESDA, Maryland, Jan. 3, 2017 PRNewswire - Cannabics Pharmaceuticals Inc. CNBX today announced development of Cannabics 5mg THC Capsule in. Cannabics pharmaceuticals Cannabics Pharmaceuticals Inc Ver nderung Vortag , Aktueller Kurs 0.0809 Cannabics pharmaceuticals Die Mitarbeiteranzahl von Cannabics Pharmaceuticals 2023 ist 0. Im Jahr 2023 besch ftigte Cannabics Pharmaceuticals 0 Mitarbeiter, eine Ver nderung um 0 im Vergleich zur Anzahl Cannabics pharmaceuticals Zu der Cannabics Pharmaceuticals Aktie WKN A116WM, ISIN US13764M1009 finden Sie hier Analysen, News, Kurse, Charts, Diskussionen,.Die Aktienkurse aller wichtigen B rsenpl tze zu Cannabics Pharmaceuticals-Aktie auf einen Blick. Aktienkurse, Ums tze, Ask, Bid, Volumen der B rsenpl tze von Cannabics Pharmaceuticals-Aktie. Cannabics pharmaceuticals Cannabics Pharmaceuticals Inc. B rsenempfehlungen, Analysen, Trading- und Anlagestrategie f r Aktie Cannabics Pharmaceuticals Inc. A116WM US13764M1009 Other OTC Cannabics pharmaceuticals Introduction to Cannabics Pharmaceuticals Inc. Lab Cannabics pharmaceuticals Cannabics Pharmaceuticals Inc. ENVIRONMENTAL, SOCIAL AND GOVERNANCE ESG POLICY August 2021 ABOUT THE COMPANY Cannabics Pharmaceuticals Inc. Cannabics Cannabics pharmaceuticals Cannabics Pharmaceuticals CNBX IR FORM 10-K A 2014Q4 Cannabics pharmaceuticals Cannabics pharmaceuticals Der Umsatz von Cannabics Pharmaceuticals 2023 ist 0. Cannabics pharmaceuticals Cannabics Pharmaceuticals Inc. News, Nachrichten und Informationen Aktie Cannabics Pharmaceuticals Inc. A116WM US13764M1009 Other OTC Cannabics pharmaceuticals Die Anzahl an Aktien von Cannabics Pharmaceuticals 2024 ist 8,82 Mio. Im Jahr 2024 hatte Cannabics Pharmaceuticals 8,82 Mio. ausstehende Aktien, eine Ver nderung um Cannabics pharmaceuticals Cannabics Pharmaceuticals Inc. ENVIRONMENTAL, SOCIAL AND GOVERNANCE ESG POLICY August 2021 ABOUT THE COMPANY Cannabics Pharmaceuticals Inc. Cannabics or the Company is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. Cannabics has been conducting research on the Cannabics pharmaceuticals Cannabics Pharmaceuticals Inc. Termine, berblick zu den Ergebnisver ffentlichungen und Analystensch tzungen f r das Unternehmen Cannabics Cannabics pharmaceuticals Cannabics Pharmaceuticals is headquartered in United States Maryland. Cannabics Pharmaceuticals was founded in 2012. Related Topics. Health care. Login to view all basic info. Data Snapshot. 2. News. High Related Markets. Mentioned companies in the market reports of major market categories and sectors by Cannabics Pharmaceuticals . Cannabics pharmaceuticals Cannabics Pharmaceuticals Inc. Termine, berblick zu den Ergebnisver ffentlichungen und Analystensch tzungen f r das Unternehmen Cannabics Cannabics pharmaceuticals Just Announced Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program. Cannabics pharmaceuticals Cannabics Pharmaceuticals CNBX IR FORM 10-K 2014Q4 Cannabics pharmaceuticals Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals TEL AVIV, Israel and BETHESDA, Md., March 28, 2022 PRNewswire - Cannabics Pharmaceuticals Inc. OTCQB CNBX , a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has changed its corporate name to CNBX Pharmaceuticals Cannabics pharmaceuticals
Cannabics Pharmaceuticals Inc OTCMKTS CNBX Concludes Cannabics
CANNABICS PHARMACEUTICALS INC. - SEC.gov